Overview

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
Phase:
Phase 2
Details
Lead Sponsor:
ObsEva SA
Treatments:
OBE2109